icon-folder.gif   Conference Reports for NATAP  
 
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
 
 
 
Predictors of Virologic Response with Telaprevir-based Combination Treatment in HCV Genotype 1-infected Patients with Prior Peginterferon/ribavirin Treatment Failure: Post-hoc Analysis of the Phase III REALIZE Study
 
 
  Reported by Jules Levin
AASLD Nov 5-9 2011
 
T Berg,1 P Andreone,2 S Pol,3 S Roberts,4 Z Younossi,5 M Diago,6 EJ Lawitz,7 R Focaccia,8 GR Foster,9 A Horban,10 I Lonjon-Domanec,11 R DeMasi,12 G Picchio,12 J Witek,12 S Zeuzem13
 
1Universitńtsklinikum Leipzig, Sektion Hepatologie, Klinik fur Gastroenterologie und Rheumatologie, Leipzig, Germany; 2Universita di Bologna, Bologna, Italy; 3UniversitÚ Paris Descartes, INSERM UnitÚ 1016, and Assistance Publique-Hopitaux de Paris, Cochin Hospital, Paris, France; 4Department of Gastroenterology, Alfred Hospital, Melbourne, VIC, Australia; 5Center for Liver Diseases and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; 6Hospital General de Valencia, Valencia, Spain; 7Alamo Medical Research, San Antonio, TX, USA; 8Emilio Ribas Infectious Diseases Institute, Sao Paulo, Brazil; 9Queen Marys University of London, Institute of Cell and Molecular Science, London, UK; 10Medical University of Warsaw, Wolska, Warsaw, Poland; 11Janssen Pharmaceuticals, Paris, France; 12Tibotec Inc., Titusville, NJ, USA, 13Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif